Cryo-Cell International Inc (CCEL)
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$4.28+0.94%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · CCEL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -66.6% |
| Our one-year growth estimate | diamond | -7.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 59.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 27 industry peers
CCEL — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-05-08
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the NYSE American LLC ("NYSE American"). As previously disclosed, the Company submitted a compliance plan to NYSE American on April 8, 2026. NYSE Regulation accepted the plan and…
Why it matters: Higher income means better cost control and efficiency. This can boost investor confidence.
Supportive ifQ2 income shows a big increase from Q1's $765,134.
Worry ifIncome falls or stays below $765,134 in Q2.
Why it matters: The earnings report will show if the company can improve its financial losses. Investors look for signs of recovery.
Watch forThe earnings report shows smaller losses. It may also show profits again.
Also watch forThe earnings report shows ongoing losses. There is no improvement in finances.
Why it matters: Regaining compliance is crucial for Cryo-Cell to maintain its NYSE listing. A failure could lead to delisting.
Worry ifCryo-Cell successfully meets NYSE compliance standards by the next review period.
Less concerning ifCryo-Cell got another notice from NYSE about not following rules.
Why it matters: Updates from NYSE can impact investor confidence and stock performance. Compliance is critical for the company’s future.
Worry ifNYSE confirms Cryo-Cell's compliance plan is accepted and no further notices are issued.
Less concerning ifNYSE issues a new notice of delisting or non-compliance.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$229 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $539 loss on $10,000 · 5.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,138 loss on $10,000 · 41.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The spinoff could impact the company's focus and resources. Clarity on this could affect investor sentiment.
Watch forManagement announces a clear timeline or strategy for the Celle Corp. spinoff.
Also watch forManagement indicates delays or halts plans for the Celle Corp. spinoff.
Why it matters: Sector growth impacts Cryo-Cell's performance. Slowing sector growth could signal challenges for the company.
Watch forHealth care revenue growth remains above the median, indicating a strong sector.
Also watch forHealth care revenue growth drops below its median, suggesting sector challenges.
Why it matters: Regaining compliance is crucial for Cryo-Cell's continued listing on the NYSE. Failure could lead to delisting.
Worry ifThe company meets NYSE compliance standards by the next evaluation date.
Less concerning ifThe company does not meet NYSE compliance standards and gets another delisting notice.
Why it matters: Higher operating income means better cost management. This helps the company grow over time.
Supportive ifQ2 operating income was over $765,134. This keeps the positive trend going.
Worry ifOperating income falls back into a loss for Q2.
Why it matters: A drop in sector revenue growth may mean bigger problems for Cryo-Cell.
Worry ifSector revenue growth reported below its median for the current growth phase.
Less concerning ifSector revenue growth remains above the median.
Why it matters: Regaining compliance is crucial for Cryo-Cell to remain listed on the NYSE American. Failure to comply could lead to delisting.
Worry ifManagement says they will show progress in compliance by the earnings call on October 21, 2026.
Less concerning ifNo significant progress reported on compliance plan by the next earnings call.
Why it matters: Better operating income shows the company is healthy and managed well. This can help investors.
Supportive ifOperating income was over $1.20M for Q3 2026.
Worry ifOperating income falls below $1.20M for Q3 2026.